Seminars in Arthritis and Rheumatism
Volume 37, Issue 3 , Pages 137-148, December 2007

Schnitzler Syndrome: Beyond the Case Reports: Review and Follow-Up of 94 Patients with an Emphasis on Prognosis and Treatment

  • Heleen D. de Koning, MSc
  • ,
  • Evelien J. Bodar, MD
  • ,
  • Jos W.M. van der Meer, MD, PhD
  • ,
  • Anna Simon, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Anna Simon, MD, PhD, Division of General Internal Medicine, 484, Department of Internal Medicine, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
  • ,
  • Schnitzler Syndrome Study Group

Division of General Internal Medicine, Department of Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

published online 22 June 2007.

Objective

Schnitzler syndrome is a rare disorder characterized by a chronic urticarial rash and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis, bone pain, and lymphadenopathy. Our objectives are to systematically review disease characteristics of Schnitzler syndrome and collect follow-up information to gain insight into treatment efficacy and long-term prognosis.

Methods

PubMed and MEDLINE databases (1966-2006) were searched, using the key words “Schnitzler syndrome,” and the combination of “urticaria” with “monoclonal gammopathy,” “immunoglobulin M (IgM),” or “paraproteinemia,” as well as secondary references. Data on a total of 94 patients who met the criteria for Schnitzler syndrome were reviewed. Questionnaires sent to all authors retrieved additional follow-up data on 43 patients, resulting in a mean follow-up of 9.5 years after onset of symptoms, and a follow-up of 20 years or more in 10 patients.

Results

Symptoms, signs, and laboratory findings as found in the 94 patients are reviewed in detail. There have been promising developments in therapeutic options, especially antiinterleukin-1 treatment, which induced complete remission in all 8 patients treated so far. To date, no spontaneous complete remissions have been reported. Patients with Schnitzler syndrome showed no increased mortality during the present follow-up. However, they had a 10-year risk of 15% of developing a lymphoproliferative disorder, most notably Waldenström’s macroglobulinemia. Three cases of type amyloid A (AA) amyloidosis associated with Schnitzler syndrome were reported.

Conclusions

Schnitzler syndrome is a disabling disorder which affects multiple systems and which can be considered as an autoinflammatory syndrome. There are new, effective treatment options, but close monitoring remains warranted because of the increased risk of lymphoproliferative disease.

Keywords: Schnitzler syndrome, urticaria, monoclonal gammopathy, autoinflammatory, Waldenström’s macroglobulinemia, anakinra

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 H.D.K. is supported by a grant from Studiefonds Ketel 1; A.S. is supported by a ZonMW Veni grant.

PII: S0049-0172(07)00073-X

doi:10.1016/j.semarthrit.2007.04.001

Seminars in Arthritis and Rheumatism
Volume 37, Issue 3 , Pages 137-148, December 2007